l e t t e r s 2 6 4 VOLUME 21 | NUMBER 3 | MARCH 2015 nature medicine are structurally related to BHB, did not affect ATP-induced NLRP3 activation (Fig. 1b) . We sought to determine whether BHB specifically targets ATP-induced inflammasome activation or common signaling mechanisms in response to structurally diverse NLRP3 activators. BHB, but not butyrate, inhibited monosodium urate (MSU) crystal-and particulate matter-induced caspase-1 activation ( Fig. 1c and Supplementary Fig. 1b) . Furthermore, BHB blocked inflammasome activation by five additional NLRP3 activators: nigericin; silica particles ( Supplementary Fig. 1b) ; and the lipotoxic fatty acids palmitate, ceramide, and sphingosine ( Fig. 1d) . BHB also inhibited Figure 1 BHB specifically inhibits the NLRP3 inflammasome. (a) Representative western blot analysis of caspase-1 (casp1; active subunit p20) and IL-1β (active p17) in the supernatant of BMDMs primed with LPS for 4 h and stimulated with ATP for 1 h in the presence of various concentrations of d-BHB. Procasp1, procaspase-1, biologically inactive; Pro-IL-1β, non-secreted biologically inactive form of IL-1β. (b) Western blot analysis of caspase-1 activation in BMDMs stimulated with LPS and ATP and treated with BHB (10 mM), butyrate (10 mM), AcAc (10 mM) or acetate (10 mM). Western blot analysis of caspase-1 activation in LPS-primed BMDMs stimulated with (c) MSU and treated with butyrate or d-BHB, or (d) nigericin (10 µM) for 1 h, palmitate (200 µM) for 24 h, C6 ceramide for 6 h (80 µg/ml), and sphingosine (50 µM) for 1 h and treated with BHB. (e) Western blot analysis of IL-1β activation in BMDMs primed with the TLR ligands lipid A, Pam3-CSK (Pam3) or LTA for 4 h and stimulated with ATP and increasing doses of d-BHB for 1 h. Active IL-1β (p17) was analyzed in supernatants by western blotting. IL-1β (f) or caspase-1 activation (g) in BMDMs infected with (f) F. tularensis or (g) S. typhimurium and treated with different doses of BHB. Data are expressed as mean ± sem (*P < 0.05) from cells derived from n = 12 (a-d); n = 6 (e); or n = 3 (f,g) mice with each independent experiment each carried out in triplicate (a-d,e) or in duplicate (f,g). All bar graphs in a-e represent quantitation of p20 caspase-1 band intensity as fold change by normalizing to inactive p48 procaspase-1, or p17 IL-1β band intensity as fold change by normalizing to inactive p37 pro-IL-1β. The differences between means and the effects of treatments were determined by one-way analysis of variance (ANOVA) using Tukey's test. the processing of IL-1β in response to the Toll-like receptor 4 (TLR4) pathogen-associated molecular pattern (PAMP) agonist lipid A, the TLR1/2 ligand Pam3-CSK4 and the TLR2 agonist lipoteichoic acid (LTA) (Fig. 1e) . We next investigated the specificity of BHB to NLRP3 as compared to other inflammasomes. The BMDMs were infected with either Francisella tularensis to activate the AIM2 inflammasome or Salmonella typhimurium to activate the NLRC4 inflammasome. BHB did not inhibit either AIM2 inflammasome-induced IL-1β activation (Fig. 1f) or NLRC4-mediated caspase-1 cleavage (Fig. 1g) . Given that the inflammasome can also be activated by LPS through caspase-11 activation independently of TLR4 (refs. 20,21), we also evaluated the non-canonical inflammasome pathway. Our data indicate that neither butyrate nor BHB blocks caspase-11 activation (Supplementary Fig. 1c) . These results suggest that BHB acts on a central, common signaling pathway specific to the NLRP3 inflammasome in response to PAMPs and a wide array of pro-inflammatory DAMPs.
The ketone bodies b-hydroxybutyrate (BHB) and acetoacetate (AcAc) support mammalian survival during states of energy deficit by serving as alternative sources of ATP 1 . BHB levels are elevated by starvation, caloric restriction, high-intensity exercise, or the low-carbohydrate ketogenic diet 2 . Prolonged fasting reduces inflammation; however, the impact that ketones and other alternative metabolic fuels produced during energy deficits have on the innate immune response is unknown [2] [3] [4] [5] [6] . We report that BHB, but neither AcAc nor the structurally related shortchain fatty acids butyrate and acetate, suppresses activation of the NLRP3 inflammasome in response to urate crystals, ATP and lipotoxic fatty acids. BHB did not inhibit caspase-1 activation in response to pathogens that activate the NLR family, CARD domain containing 4 (NLRC4) or absent in melanoma 2 (AIM2) inflammasome and did not affect non-canonical caspase-11, inflammasome activation. Mechanistically, BHB inhibits the NLRP3 inflammasome by preventing K + efflux and reducing ASC oligomerization and speck formation. The inhibitory effects of BHB on NLRP3 are not dependent on chirality or starvationregulated mechanisms like AMP-activated protein kinase (AMPK), reactive oxygen species (ROS), autophagy or glycolytic inhibition. BHB blocks the NLRP3 inflammasome without undergoing oxidation in the TCA cycle, and independently of uncoupling protein-2 (UCP2), sirtuin-2 (SIRT2), the G protein-coupled receptor GPR109A or hydrocaboxylic acid receptor 2 (HCAR2). BHB reduces NLRP3 inflammasomemediated interleukin (IL)-1b and IL-18 production in human monocytes. In vivo, BHB or a ketogenic diet attenuates caspase-1 activation and IL-1b secretion in mouse models of NLRP3-mediated diseases such as Muckle-Wells syndrome, familial cold autoinflammatory syndrome and urate crystal-induced peritonitis. Our findings suggest that the anti-inflammatory effects of caloric restriction or ketogenic diets may be linked to BHB-mediated inhibition of the NLRP3 inflammasome.
The NLRP3 inflammasome controls the activation of caspase-1 and the release of the pro-inflammatory cytokines IL-1β and IL-18 in macrophages [7] [8] [9] [10] [11] . It is an important innate immune sensor that is activated in response to structurally diverse damage-associated molecular patterns (DAMPs) such as toxins 8 , ATP 8 , excess glucose 7 , ceramides 12 , amyloids 13, 14 , urate 15 and cholesterol crystals 16 . Ablation of NLRP3 attenuates type 2 diabetes 12, 14, 17 , atherosclerosis 16 , multiple sclerosis 18 , Alzheimer disease 14 , age-related functional decline 19 , bone loss 19 and gout 15 . Thus, identification of endogenous mechanisms that control NLRP3 inflammasome deactivation may provide insights into the control of several chronic diseases. Although it is known that immune-metabolic interactions dampen pro-inflammatory responses via glycolysis inhibition 6 , it is not known whether the alternative metabolic fuels that are produced during energy deficits, such as ketones, impact the innate immune response.
The ketone bodies β-hydroxybutyrate (BHB) and acetoacetate (AcAc) are produced in the liver of mammals and serve as alternative energy sources for the brain, heart, and skeletal muscles during nutrient deprivation and adherence to low carbohydrate diets 1, 2 . With prolonged fasting, circulating concentrations of BHB can increase to as much as 6-8 mM as liver glycogen stores get used 1,2 . These nutritional states are associated with altered immune cell function, but it is unknown whether ketone bodies serve as immune effectors.
To test whether BHB affects inflammasome activation, we treated lipopolysaccharide (LPS)-primed mouse bone marrow-derived macrophages (BMDMs) with the NLRP3 activator ATP along with BHB for 60 min and measured caspase-1 activation using a western blot that detects the enzymatically active p20 subunit of caspase-1. BHB dose-dependently inhibited both the ATP-induced cleavage of caspase-1 into p20 and the processing of the biologically active p17 form of IL-1β. This inhibition occurred at BHB concentrations similar to the BHB elevations induced by strenuous exercise or 2 d of fasting 1, 2 (Fig. 1a and Supplementary Fig. 1a) . AcAc and the microbiota-derived short-chain fatty acids butyrate and acetate, which
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npg the processing of IL-1β in response to the Toll-like receptor 4 (TLR4) pathogen-associated molecular pattern (PAMP) agonist lipid A, the TLR1/2 ligand Pam3-CSK4 and the TLR2 agonist lipoteichoic acid (LTA) (Fig. 1e) .
We next investigated the specificity of BHB to NLRP3 as compared to other inflammasomes. The BMDMs were infected with either Francisella tularensis to activate the AIM2 inflammasome or Salmonella typhimurium to activate the NLRC4 inflammasome. BHB did not inhibit either AIM2 inflammasome-induced IL-1β activation (Fig. 1f) or NLRC4-mediated caspase-1 cleavage (Fig. 1g) . Given that the inflammasome can also be activated by LPS through caspase-11 activation independently of TLR4 (refs. 20,21) , we also evaluated the non-canonical inflammasome pathway. Our data indicate that neither butyrate nor BHB blocks caspase-11 activation ( Supplementary Fig. 1c ). These results suggest that BHB acts on a central, common signaling pathway specific to the NLRP3 inflammasome in response to PAMPs and a wide array of pro-inflammatory DAMPs.
Prolonged fasting and subsequent increases in circulating BHB are linked to a reduction in oxidative stress 22 , increased AMPK activity 23 and autophagy 24 . All of these mechanisms have also been implicated in regulating the NLRP3 inflammasome 8 . Consistent with recent data 25 , ROS damage via rotenone or hydrogen peroxide ( Fig. 2a;  Supplementary Fig. 2a,b) was not sufficient to induce caspase-1 cleavage and did not abrogate the suppressive effects of BHB on ATP-induced NLRP3 inflammasome activation. Caspase-1 activation was induced by LPS priming alone in macrophages deficient in the autophagy regulator Atg5 (Fig. 2b and Supplementary Fig. 2a) . However, absence of Atg5 did not alter the inhibitory effects of BHB on the inflammasome (Fig. 2b and Supplementary Fig. 2a) . Consistent with these findings, the autophagy inhibitor 3-methyladenine (3-MA) and the proteasome blocker epoxomicin did not abrogate BHB's suppressive effects on ATP-induced NLRP3 inflammasome activation ( Fig. 2c and Supplementary Fig. 2a) . The activation of AMPK using AICAR (Fig. 2d) Figs. 2c and 3a) . Furthermore, inhibition of AMPK via compound C did not abrogate BHB's inhibitory effects on NLRP3-mediated caspase-1 activation. (Fig. 2d and Supplementary   Figs. 2a,c and 3a) . BHB also did not impair the viability of BMDMs, and, at a concentration of 10 mM, it increased cellular proliferation (Fig. 2e) . It has been suggested that BHB can act as a signaling molecule by binding the G protein-coupled receptor GPR109a (ref. 26) or by serving as a histone deacetylase (HDAC) inhibitor 22 . Inhibition of HDACs using trichostatin A (TSA) did not affect inflammasome activation in LPS-primed and NLRP3 agonist-treated macrophages ( Fig. 2f and  Supplementary Fig. 2a ) despite induction of H3 acetylation by BHB in macrophages (Supplementary Fig. 3b) . To understand the role of GPR109a in BHB's effects on macrophages, we used niacin, a GPR109a ligand that has been reported to inhibit colonic inflammation 27 . We found that, unlike BHB, niacin did not block NLRP3 inflammasome activation ( Fig. 2f and Supplementary Fig. 2a) . The effects of BHB on the inflammasome were not altered in GPR109A-deficient BMDMs (Fig. 2f,g; Supplementary Fig. 2a) , and neither butyrate nor AcAc altered NLRP3 inflammasome activity in either GPR109A-sufficient or -deficient cells (Fig. 2g and Supplementary Fig. 2a) . BHB is a chiral compound and its enantiomer, (S)-BHB, cannot enter the TCA cycle but binds GPR109A with high affinity 26 . We found that (S)-BHB exhibited effects on the inflammasome that were similar to d-BHB as it did not require GPR109A to block NLRP3 (Fig. 2h) .
Compared to fatty acids, oxidation of BHB is energetically more efficient as all reducing equivalents generated by ketone oxidation are delivered through NADH to complex-I within the mitochondrial electron transport chain 2 . Furthermore, ketone oxidation increases the redox span between complex I and complex III by keeping mitochondrial ubiquinone oxidized 28 . We wanted to know whether oxidation, entry into the TCA cycle, or reduced mitochondrial stress mediate d-BHB's effects on the inflammasome. Macrophages express ketogenic and ketolytic enzymes encoded by Acat1, Bdh1, Bdh2 and Hmgcl Supplementary Fig. 4a-c) . In terms of macrophage polarization, classically activated M1 macrophages showed a reduction in the expression of Acat1, Bdh1, Bdh2 and Hmgcl as compared to M2 macrophages, suggesting that ketones may affect macrophage polarization (Supplementary Fig. 4b ). In addition, LPS induced protein expression of the ketolytic enzyme Scot (succinyl-CoA:3-oxo-acid CoA-transferase, encoded by Oxct) and the ketogenic enzyme Hmgcl in BMDMs (Supplementary Fig. 4c) . However, the TCA cycle entryinhibitor aminoxyacetate did not inhibit the effects of BHB on the inflammasome (Supplementary Fig. 4d) , and the enantiomer (S)-BHB (which does not enter the TCA cycle) efficiently blocked NLRP3 inflammasome activation (Supplementary Fig. 4e ). To directly assess the role of BHB oxidation, we specifically deleted the ketolytic mitochondrial enzyme Scot 27 in macrophages ( Fig. 3a; Supplementary  Fig. 4f ). These experiments confirmed that the TCA intermediates generated through ketone body oxidation in macrophage mitochondria did not mediate the suppressive effects of BHB on the NLRP3 inflammasome ( Fig. 3a; Supplementary Fig. 4f ). (n = 6 per group). Data are expressed as mean ± sem (*P < 0.05) and statistical differences between means and the effects of treatments were determined by one-way ANOVA using Tukey's test (a,d,e).
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The NAD-dependent deacetylase SIRT2 regulates acetylation of α-tubulin, which controls microtubule-driven apposition of NLRP3 and ASC 29 . Inhibition of SIRT2 by the small molecule AGK2 activates the NLRP3 inflammasome and supplementation with NAD + lowers IL-1β secretion from macrophages 29 . Inhibition of SIRT2 by AGK2 or ablation of either SIRT2 or uncoupling protein 2 (UCP2), a mitochondrial anion transporter did not abrogate the effects of BHB on the inflammasome, and the addition of NAD + did not block caspase-1 activation in response to LPS and ATP (Fig. 3b-d and Supplementary  Fig. 4f ). These findings rule out a major role for mitochondrial ROS in the effects of ketone bodies on the inflammasome.
BHB is a strongly anionic endogenous molecule 2 , and it exerts antiepileptic effects by reducing neuronal excitability via regulation of intracellular potassium cations 30 . Consistent with recent studies that demonstrate that K + efflux triggers NLRP3 inflammasome activation 8, 25 , BHB prevented the decline of intracellular K + in response to incubation with the NLRP3 activators ATP, MSU and ceramide (Fig. 3e-g and Supplementary Fig. 5a ). Furthermore, NLRP3-dependent, ASC nucleation-induced polymerization or oligomerization are considered to be common mechanisms of NLRP3 inflammasome activation 31, 32 . BHB prevents ATP-induced ASC oligomerization (Fig. 3h) and speck formation (Fig. 3i) . Our data suggest that BHB blocks NLRP3 inflammasome activation both by controlling an unknown upstream event that reduces K + efflux from macrophages and by inhibiting ASC polymerization, speck formation and assembly of the inflammasome.
Next we investigated whether delivery of BHB can inhibit the NLRP3 inflammasome in human monocytes and mouse models of NLRP3-driven inflammation in vivo. BHB dose-dependently inhibited IL-1β and IL-18 ( Fig. 4a) secretion in LPS-stimulated human monocytes without significantly affecting tumor necrosis factor (TNF)-α production (Supplementary Fig. 5b) . In vivo administration of BHB is insufficient to sustain high serum concentration owing to rapid clearance 1, 2, 30 . To reduce clearance, BHB was complexed with nanolipogels (nLGs) to improve its bioavailability 33 . BHB-nLGs inhibited NLRP3 inflammasome activation in macrophages (Fig. 4b) . In mice, the Nlrp3 inflammasome was activated following intraperitoneal (IP) injection of MSU crystals, resulting in an influx of neutrophils into the peritoneum and increased secretion of IL-1β by macrophages 4 h after injection 34 . Compared to mice given nLGs alone, BHB-nLGs reduced neutrophil infiltration into the peritoneum ( Fig. 4c and Supplementary Fig. 5c-e) without directly impairing neutrophil migration (Supplementary Fig. 5f ), suggesting direct effects of BHB in vivo on NLRP3-driven neutrophil influx. Peritoneal cells from MSU-injected mice treated with BHB-nLGs produced less IL-1β (Fig. 4d) and the concentration of IL-1β in the serum was reduced after BHB-nLG treatment (Fig. 4e) .
Missense mutations in NLRP3 cause systemic inflammatory diseases like Muckle-Wells syndrome (MWS) and familial cold autoinflammatory syndrome (FCAS), which are characterized by overproduction of IL-1β and IL-18 (ref. 35) . We tested the efficiency of BHB in mice that express knocked-in human NLRP3 with gain-of-function mutations (A350V and L351P) that mimic MWS and FCAS, respectively, rendering the inflammasome constitutively active without the requirement of NLRP3 ligands 35 . As described before 35 , in the FCAS mouse model, tamoxifen-induced, Cre recombinase-mediated excision of a floxed neomycin cassette induces the expression of a mutant form of NLRP3 (L351P) and subsequent inflammasome activation in macrophages (Supplementary Fig. 6a ).
Treatment of BMDMs from mouse models of MWS (NLRP3 (A350V)) ( Fig. 4f and Supplementary Fig. 5g ) and FCAS (NLRP3 (L351P)) ( Fig. 4g,h; Supplementary Fig. 5g ) with BHB-nLGs dose-dependently inhibited constitutive NLRP3 inflammasome activation. When complexed with nLGs, d-BHB inhibited inflammasome activation in FCAS macrophages at a lower dose ( Supplementary  Fig. 6b,c) . BHB reduces ASC oligomerization in macrophages upon Cre-mediated induction of NLRP (L351P) by tamoxifen treatment in vitro (Fig. 4h) . To model a ketogenic diet and elevate BHB levels in vivo, the FCAS mice were fed 1,3-butanediol ketone diesters (KD) for one week before the induction of a missense Nlrp3 mutation. The KD increased the serum BHB levels in mice to fasting levels of 0.75-1 mM. As reported previously, mouse models of FCAS (NLRP3 (L351P), Cre + ) develop severe neutrophila 35 in the peritoneum 3 d after the induction of mutant NLRP3. Compared to the chowfed FCAS model, the KD treatment protected these animals from neutrophilia ( Fig. 4i) and hyperglycemia (Supplementary Fig. 6d ), without any effects on the infiltration of CD11b + F4/80 + peritoneal macrophages (Supplementary Fig. 6e) . Furthermore,the KD diet did not affect the overall frequency of splenic T cells, macrophages or neutrophils ( Supplementary Fig. 7a-d) . Given that FCAS is caspase-1 dependent and that IL-1β and IL-18 do not influence all of the observed pathology 35 , ketogenic diets that elevate BHB may improve the therapeutic outcome of patients by inhibiting the inflammasome.
These findings suggest that the fasting-or exercise-induced metabolite BHB inhibits the NLRP3 inflammasome in macrophages independently of binding to surface GPR109A receptors or mitochondrial oxidation, which may avoid both competition for receptor occupancy and requirement for ATP generation. Thus, in states of extreme energy deficit such as starvation, metabolic signals such as BHB can dampen innate immune responses, sparing ATP for the functioning of ketone-dependent organs such as the brain and heart (Supplementary Fig. 8a ). These findings provide insight into the immunological functions of metabolic signals such as BHB and suggest that dietary or pharmacological approaches to elevate BHB-without inducing the generalized starvation response-hold promise in reducing the severity of NLRP3-mediated chronic inflammatory diseases.
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